The trial is funded through Abu Dhabi’s Healthcare Research …
The Retinal Degeneration Fund (RD Fund) is driving the future of retinal innovation through strategic investments to accelerate the development of novel therapeutics for inherited retinal diseases (IRDs) and dry Age-related Macular Degeneration (dry AMD).
The RD Fund was designed to bridge the critical funding gap between discovery stage research and drug development.
IN THE NEWS
01/20/2026
Genezen and Atsena Therapeutics Announce Strategic Commercial Manuf…
Lexington, MA and Durham, NC – [January 20, 2026] – Genezen,…
01/08/2026
Beacon Therapeutics Announces Closing of Oversubscribed Series C Fi…
- Round led by new investor Life Sciences at Goldman Sachs Al…
11/13/2025
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 P…
Emerging gene therapy administered through a one-time subret…
10/28/2025
SparingVision Doses First Patient with SPVN20 for Advanced Retiniti…
- SPVN20 aims to restore visual acuity and aspects of color v…
09/30/2025
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase…
Pediatric participants demonstrated large gains in cone-medi…
09/23/2025
Atsena Therapeutics Announces Dosing Complete for Adults in Part B…
Pediatric dosing expected to begin in Q4 2025
Pivotal cohor…
09/12/2025
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial…
NPI-001 shows more than 50% reduction in photoreceptor loss …
07/23/2025
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH1…
- Collaboration aims to accelerate development of OPGx-RDH12,…
07/09/2025
Atsena Therapeutics Releases XLRS Community Statement
This morning, Atsena issued a press release to announce that…
06/23/2025
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Supp…
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE)…
06/09/2025
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer
- Experienced global leader in ophthalmology and gene therapy…